Cargando…
Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies
Immunotherapies are at the forefront of the fight against cancers, and researchers continue to develop and test novel immunotherapeutic modalities. Ideal cancer immunotherapies induce a patient’s immune system to kill their own cancer and develop long-lasting immunity. Research has demonstrated a cr...
Autores principales: | van Vloten, Jacob P., Santry, Lisa A., McAusland, Thomas M., Karimi, Khalil, McFadden, Grant, Petrik, James J., Wootton, Sarah K., Bridle, Byram W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369252/ https://www.ncbi.nlm.nih.gov/pubmed/30788384 http://dx.doi.org/10.1016/j.omtm.2019.01.012 |
Ejemplares similares
-
Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies
por: van Vloten, Jacob P., et al.
Publicado: (2019) -
Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy
por: van Vloten, Jacob P., et al.
Publicado: (2021) -
Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer
por: van Vloten, Jacob P, et al.
Publicado: (2022) -
Production and Purification of High-Titer Newcastle Disease Virus for Use in Preclinical Mouse Models of Cancer
por: Santry, Lisa A., et al.
Publicado: (2017) -
Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
por: Minott, Jessica A., et al.
Publicado: (2022)